Contineum Therapeutics (CTNM) Cash from Operations (2023 - 2026)

Contineum Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 11501000.0 for Q2 2026.

• In Q2 2026, Cash from Operations rose 26.56% year-over-year to 11501000.0; the TTM figure through Jun 2026 stood at 53006000.0 (down 14.13% YoY), while the FY2025 annual figure was 55312000.0, down 68.4% from the prior year.
• Cash from Operations for Q2 2026 stood at 11501000.0, up from 16266000.0 in the prior quarter.
• The five-year high for Cash from Operations was 40674000.0 in Q2 2023, with the low at 16266000.0 in Q1 2026.
• The 4-year median for Cash from Operations is 10453000.0 (2023), against an average of 6898214.29.
• The sharpest annual moves came in 2024 and 2026: Cash from Operations plunged 120.9% in 2024, then increased 26.56% in 2026.
• Contineum Therapeutics' Cash from Operations stood at 10704000.0 in 2023, then grew by 4.69% to 10202000.0 in 2024, then slipped by 27.84% to 13042000.0 in 2025, then advanced by 11.82% to 11501000.0 in 2026.
• Business Quant data shows CTNM's Cash from Operations at 11501000.0 in Q2 2026, 16266000.0 in Q1 2026, and 13042000.0 in Q4 2025.